What is the CRISPR patent dispute about?

It's a fight over who invented CRISPR-Cas9 for eukaryotic (human-like) cells first: Broad Institute/MIT/Harvard vs. UC Berkeley/Charpentier/Vienna.

Who won the CRISPR patents?

Broad Institute holds priority in the U.S. for eukaryotic applications, per PTAB's latest ruling.

Will this affect CRISPR therapies coming to market?

Yes — clearer paths but higher licensing costs, potentially delaying affordable treatments by hiking startup expenses.

©️ IP & Copyright

Broad Institute Locks Down CRISPR Crown — Again — as PTAB Rejects UC's Last Shot

Lab researchers and biotech founders just got a stark reminder: CRISPR's patent throne belongs to Broad Institute. PTAB's latest ruling crushes UC's priority bid, reshaping who pays to edit genes.

theAIcatchup Apr 09, 2026 4 min read

Gavel striking on CRISPR DNA helix with Broad Institute and UC Berkeley logos

⚡ Key Takeaways

PTAB reaffirms Broad's first-to-invent status for eukaryotic CRISPR on remand. 𝕏
CVC fails to prove conception despite CAFC's standard tweak; provisionals lack description. 𝕏
Biotech market tilts to Broad licensees, with licensing fees set to surge. 𝕏

Published by

theAIcatchup

Where law meets technology.

#Broad Institute #CRISPR #PTAB #gene editing #patent interference

Worth sharing?

Get the best Legal Tech stories of the week in your inbox — no noise, no spam.

Originally reported by IPWatchdog

⚡ Key Takeaways

The 60-Second TL;DR

theAIcatchup

Share this article

Worth sharing?

Related Stories

85% of PTAB Patents Face Parallel Court Battles: Congress's AIA Tilted the Scales

Professors Slam PTAB's ODP Pivot in High-Stakes Baurin Rehearing

USPTO Crushes IPR Institutions by 43%: Patent Defenders Win Big

STRONGER Patents Act's Validity Loophole: Shield or Trap for Inventors?

Stay in the loop